Whole Body Magnetic Resonance Imaging With Diffusion Weighted Imaging : Potential Role in Neurofibromatosis

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01777451

Acronym

NEFIMAR

Enrollment

Registered

2013-01-28

Start date

2010-12-31

Completion date

2014-01-31

Last updated

2013-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diffusion Magnetic Resonance Imaging, Magnetic Resonance Imaging, Neurofibromatosis 1, Peripheral Nerve Sheath Tumors, Malignant, Whole Body Imaging

Keywords

Whole Body Imaging, Magnetic Resonance Imaging, Neurofibromatosis 1, Diffusion Magnetic Resonance Imaging, Peripheral Nerve Sheath Tumors, Malignant

Brief summary

Whole body MRI will be performed in patients with neurofibromatosis Type 1 PURPOSE 1: To determine the total tumor load (neurofibroma) and to diagnose plexiform neurofibromas or malignant peripheral nerve sheath tumors. All patients will be scanned two years after the baseline whole body MRI to investigate to investigate the changes of total tumor load. PURPOSE 2: added value of diffusion weighted imaging in diagnosis of high-risk neurofibromas PURPOSE 3 : to determine the apparent diffusion coefficient of the malignant nerve sheath tumors and neurofibroma. PURPOSE 4 : correlation between histopathology of the surgically resected neurofibroma/malignant nerve sheath tumors and MRI findings

Interventions

OTHERAdditional imaging or surgery

No specific intervention is necessary. If a suspicious lesion is diagnosed on MRI, further investigation will be planned (PET-CT or surgery - biopsy)

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

6 Years to 50 Years

Healthy volunteers

Inclusion criteria

* Patients with neurofibromatosis type 1, between 6 and 50 years old

Exclusion criteria

* Patients who are not allowed to be scanned on MRI (contra-indications: pacemaker ed.)

Design outcomes

Primary

Measure	Time frame	Description
Estimation of total tumor load and diagnosis of high-risk neurofibromas	1 month	Estimation of the total tumor load of neurofibromas with whole body MRI (head to knee). Diagnosis of high risk neurofibroma in the chest, abdomen, pelvis, and extremities with T2-weighted sequence and diffusion weighted sequence.

Secondary

Measure	Time frame	Description
To diagnose high-risk neurofibroma	2 months	Some patients with neurofibromatosis have lesions, pre-malignant or malignant neurofibromas. Additional imaging (PET-CT), a biopsy or surgical treatment is necessary in combination with histopathology of the lesion.

Countries

Belgium

Contacts

Primary ContactSteven Pans, MD

steven.pans@uzleuven.be3216340505s

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026